Conatus Pharmaceuticals Inc (CNAT) Expected to Announce Quarterly Sales of $9.50 Million
Equities research analysts forecast that Conatus Pharmaceuticals Inc (NASDAQ:CNAT) will post $9.50 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have made estimates for Conatus Pharmaceuticals’ earnings, with estimates ranging from $8.72 million to $10.10 million. Conatus Pharmaceuticals reported sales of $800,000.00 during the same quarter last year, which indicates a positive year-over-year growth rate of 1,087.5%. The business is scheduled to issue its next earnings results on Wednesday, March 21st.
According to Zacks, analysts expect that Conatus Pharmaceuticals will report full year sales of $9.50 million for the current year, with estimates ranging from $35.29 million to $36.70 million. For the next year, analysts forecast that the company will post sales of $60.35 million per share, with estimates ranging from $39.50 million to $116.00 million. Zacks’ sales calculations are a mean average based on a survey of sell-side analysts that cover Conatus Pharmaceuticals.
Conatus Pharmaceuticals (NASDAQ:CNAT) last posted its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.08). Conatus Pharmaceuticals had a negative return on equity of 83.02% and a negative net margin of 80.98%. The business had revenue of $9.57 million for the quarter, compared to analyst estimates of $16.06 million. During the same quarter in the prior year, the business earned ($0.31) earnings per share.
Several research firms recently commented on CNAT. Seaport Global Securities reiterated a “buy” rating and set a $16.00 target price on shares of Conatus Pharmaceuticals in a research report on Friday, October 6th. Zacks Investment Research upgraded shares of Conatus Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, October 3rd. Finally, HC Wainwright reiterated a “buy” rating and set a $17.00 target price (down from $18.00) on shares of Conatus Pharmaceuticals in a research report on Thursday, November 2nd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $14.00.
Shares of Conatus Pharmaceuticals (NASDAQ:CNAT) opened at $4.67 on Thursday. The company has a current ratio of 2.69, a quick ratio of 2.69 and a debt-to-equity ratio of 0.41. Conatus Pharmaceuticals has a 1 year low of $3.88 and a 1 year high of $9.40. The company has a market cap of $140.13, a P/E ratio of -5.77 and a beta of 1.10.
Several hedge funds and other institutional investors have recently modified their holdings of CNAT. Russell Investments Group Ltd. acquired a new position in shares of Conatus Pharmaceuticals in the 2nd quarter worth approximately $679,000. Schwab Charles Investment Management Inc. acquired a new position in shares of Conatus Pharmaceuticals in the 2nd quarter worth approximately $1,041,000. Rhumbline Advisers acquired a new position in shares of Conatus Pharmaceuticals in the 2nd quarter worth approximately $156,000. State of Wisconsin Investment Board acquired a new position in shares of Conatus Pharmaceuticals in the 2nd quarter worth approximately $115,000. Finally, Bank of New York Mellon Corp lifted its position in shares of Conatus Pharmaceuticals by 62.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 130,343 shares of the biotechnology company’s stock worth $751,000 after purchasing an additional 50,033 shares during the period. Hedge funds and other institutional investors own 36.84% of the company’s stock.
Conatus Pharmaceuticals Company Profile
Conatus Pharmaceuticals Inc is a biotechnology company. The Company focuses on the development and commercialization of medicines to treat liver disease. The Company operates through commercialization and development of pharmaceutical products segment. The Company is engaged in developing emricasan, which is an orally active pan-caspase protease inhibitor for the treatment of patients with chronic liver disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with Analyst Ratings Network's FREE daily email newsletter.